| Drug General Information |
| Drug ID |
D09YHO
|
| Former ID |
DNC003496
|
| Drug Name |
Compound 67
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Formula |
C17H15N5
|
| Canonical SMILES |
CC1=CC=CC(=N1)C2=C(CNN2)C3=NC4=C(C=C3)N=CC=C4
|
| InChI |
1S/C17H15N5/c1-11-4-2-5-16(20-11)17-12(10-19-22-17)13-7-8-14-15(21-13)6-3-9-18-14/h2-9,19,22H,10H2,1H3
|
| InChIKey |
YRBHUKMLAGQYHS-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
TGF-beta receptor type I |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
TGF-beta signaling pathway
|
|
Osteoclast differentiation
|
|
Hippo signaling pathway
|
|
Adherens junction
|
|
Chagas disease (American trypanosomiasis)
|
|
Hepatitis B
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Chronic myeloid leukemia
|
|
PANTHER Pathway
|
TGF-beta signaling pathway
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
ALK1 signaling events
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
TGF-beta receptor signaling
|
|
Reactome
|
TGF-beta receptor signaling activates SMADs
|
|
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
|
SMAD2/3 Phosphorylation Motif Mutants in Cancer
|
|
SMAD2/3 MH2 Domain Mutants in Cancer
|
|
TGFBR2 Kinase Domain Mutants in Cancer
|
|
TGFBR1 KD Mutants in Cancer
|
|
TGFBR1 LBD Mutants in Cancer
|
|
WikiPathways
|
TGF Beta Signaling Pathway
|
|
p38 MAPK Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Cardiac Hypertrophic Response
|
|
Signaling by TGF-beta Receptor Complex
|
|
Integrated Pancreatic Cancer Pathway
|
|
Integrated Breast Cancer Pathway
|
| References |
| REF 1 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
|---|
